clinical trial · NCT00648401
Food Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg
HealthyVerapamil Hydrochloride Extended-Release Capsules, 300 mgVerelan® PM Extended-Release Capsules, 300 mg
brief summary
The objective for this study was to investigate the bioequivalence of Mylan's verapamil HCl extended-release 300 mg capsules to Schwarz's Verelan® PM extended-release 300 mg capsules following a single, oral 300 mg (1 x 300 mg) dose administration under fed conditions.
started
Jan 1, 2006
primary completion
Jan 1, 2006
completion
Feb 1, 2006
last updated
Apr 24, 2024
official title
Single-Dose Fed Bioequivalence Study of Verapamil HCl Extended-Release Capsules (300 mg; Mylan) and Verelan® PM Extended-Release Capsules (300 mg; Schwarz) in Healthy Volunteers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol